이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

BGB-16673에 대한 연구는 이전에 Bruton 티로신 키나제 (BTK) 및 B- 세포 백혈병/림프종 2 단백질 (BCL2) 억제제에 노출 된 만성 림프구 백혈병 참가자에서의 조사자가 선택한 것과 비교하여 연구 (CaDAnCe-302)

2026년 11월 9일 업데이트: BeOne Medicines

BTK 및 BCL2 주변에 이전에 노출 된 만성 림프구 백혈병 환자에서 조사자의 선택 (idelalisib + rituximab or rituximab 또는 venetoclax + venetoclax + rituximab reattment)과 비교하여 BGB-16673에 대한 3 상, 개방-라벨, 무작위 연구

The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).

연구 개요

상세 설명

CLL (chronic lymphocytic leukemia) and SLL (small lymphocytic lymphoma) are slow-growing blood cancers that affect the same type of white blood cell (called B lymphocytes). They are considered different forms of the same disease. CLL mainly occurs in the blood and bone marrow, while SLL mainly affects the lymph nodes.

Tacabrutideg is a type of medicine called a BTK degrader. BTK (Bruton's tyrosine kinase) is a protein that helps cancer cells survive. Tacabrutideg is designed to attach to the BTK protein and tag it for removal, so that the body's own cellular "clean-up" system breaks it down and clears it away. When more BTK is removed from the body, it interferes with the signals needed for the cancer cells to multiply and survive and may also help overcome resistance caused by certain changes in BTK.

The purpose of this study is to test if tacabrutideg is safe and if it works in adults with CLL or SLL. The main goal of the study is to find the amount of time participants live without their disease getting worse after starting the study treatment.

This study has two treatment groups. Participants will be randomly assigned by chance, to one of the treatment groups. Participants and the study doctors will know what treatment is received during the study.

The study will enroll approximately 250 adults at multiple centers worldwide with CLL or SLL. The overall time to participate in this study is 36 months. Participants will make regular visits to the clinic for treatment, health checks, blood tests, and tumor and imaging tests.

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

연구 유형

중재적

등록 (추정된)

250

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Amsterdam, 네덜란드, 1081 HV
        • 모병
        • Amsterdam Umc Vu Mc
    • Busan Gwang'yeogsi
      • Seogu, Busan Gwang'yeogsi, 대한민국, 49201
        • 모병
        • Dong A University Hospital
    • Daegu Gwang'yeogsi
      • Junggu, Daegu Gwang'yeogsi, 대한민국, 41944
        • 모병
        • Kyungpook National University Hospital
    • Gyeonggi-do
      • IlsandongGu GoyangSi, Gyeonggi-do, 대한민국, 10408
        • 모병
        • National Cancer Center (Korea)
    • Jeonnam-Gwangju S.M. City
      • HwasunGun, Jeonnam-Gwangju S.M. City, 대한민국, 58128
        • 모병
        • Chonnam National University Hwasun Hospital
    • Seoul Teugbyeolsi
      • GangnamGu, Seoul Teugbyeolsi, 대한민국, 06351
        • 모병
        • Samsung Medical Center
      • SeochoGu, Seoul Teugbyeolsi, 대한민국, 06591
        • 모병
        • The Catholic University of Korea, Seoul St Marys Hospital
      • Seoul, Seoul Teugbyeolsi, 대한민국, 03080
        • 모병
        • Seoul National University Hospital
      • Augsburg, 독일, 86156
        • 모병
        • Universitatsklinikum Augsburg
      • Berlin, 독일, 10715
        • 모병
        • Praxis Am Volkspark
      • Chemnitz, 독일, 09116
        • 모병
        • Klinikum Chemnitz Ggmbh
      • Essen, 독일, 45122
        • 모병
        • Universitatsklinikum Essen (Aor)
      • Frankfurt am Main, 독일, 60389
        • 모병
        • Centrum Fur Haematologie Und Onkologie Bethanien
      • Freiburg im Breisgau, 독일, 79106
        • 모병
        • Universitatsklinikum Freiburg I Br Klinik Fur Innere Medizin I
      • Hamburg, 독일, 20251
        • 모병
        • Universitatsklinikum Hamburg Eppendorf
      • Heidelberg, 독일, 69120
        • 모병
        • Universitatsklinikum Heidelberg
      • Homburg, 독일, 66421
        • 모병
        • Universitatsklinikum Des Saarlandes
      • Koblenz, 독일, 56068
        • 모병
        • Invo Institut Fur Versorgungsforschung in Der Onkologie
      • Leipzig, 독일, 04103
        • 모병
        • Universitaetsklinikum Leipzig Aor
      • Münster, 독일, 48149
        • 모병
        • Universitatsklinikum Munster Medizinische Klinik A
    • Arkansas
      • Jonesboro, Arkansas, 미국, 72401
        • 모병
        • St Bernards Medical Center
    • California
      • Los Angeles, California, 미국, 90095-3075
        • 모병
        • UCLA Department of Medicine Hematologyoncology
      • San Diego, California, 미국, 92103-2106
        • 모병
        • Scripps Prebys Cancer Center
      • Whittier, California, 미국, 90602
        • 모병
        • Pih Health Whittier Hospital
    • Colorado
      • Aurora, Colorado, 미국, 80012-5405
        • 모병
        • Rocky Mountain Cancer Centers (Williams) Usor
      • Golden, Colorado, 미국, 80401
        • 모병
        • Intermountain Health Lutheran Hospital Cancer Center of Colorado
    • Florida
      • Fort Myers, Florida, 미국, 33912
        • 모병
        • Florida Oncology and Hematology
      • Jacksonville, Florida, 미국, 32207-8432
        • 모병
        • Baptist Md Anderson Cancer Center
      • Weston, Florida, 미국, 33331-3609
        • 모병
        • Cleveland Clinic Florida
    • Georgia
      • Atlanta, Georgia, 미국, 30322-1013
        • 모병
        • Emory University Winship Cancer Institute
      • Atlanta, Georgia, 미국, 30342
        • 모병
        • Northside Cancer Center
    • Louisiana
      • Baton Rouge, Louisiana, 미국, 70808-4365
        • 모병
        • Our Lady of the Lake Hospital
    • Maryland
      • Bethesda, Maryland, 미국, 20817-7847
        • 모병
        • American Oncology Partners of Maryland Pa
    • Michigan
      • Grand Rapids, Michigan, 미국, 49503-2560
        • 모병
        • Corewell Health the Michigan Cancer Consortium
    • Minnesota
      • Minneapolis, Minnesota, 미국, 55455-0341
        • 모병
        • University of Minnesota
    • Missouri
      • Chesterfield, Missouri, 미국, 63017
        • 모병
        • St Lukes Center For Cancer Care
      • Springfield, Missouri, 미국, 65807-5288
        • 모병
        • Oncology Hematology Associates
    • Montana
      • Billings, Montana, 미국, 59102-6746
        • 모병
        • St Vincent Frontier Cancer Center
    • Nebraska
      • Omaha, Nebraska, 미국, 68130-2042
        • 모병
        • Oncology Hematology West, Pc Dba Nebraska Cancer Specialists
    • New York
      • New York, New York, 미국, 10065-6800
        • 모병
        • Memorial Sloan Kettering Cancer Center Mskcc
      • Shirley, New York, 미국, 11967
        • 모병
        • New York Cancer and Blood Specialists
      • Syracuse, New York, 미국, 13210-2306
        • 모병
        • Suny Upstate Medical University
      • Westbury, New York, 미국, 11590-5119
        • 모병
        • Optum Medical Care, Pc
    • Ohio
      • Cleveland, Ohio, 미국, 44106-1716
        • 모병
        • University Hospitals
      • Dayton, Ohio, 미국, 45415
        • 모병
        • Dayton Physician Network
    • Oregon
      • Eugene, Oregon, 미국, 97401
        • 모병
        • Oncology Associates of Oregon Willamette Valley Cancer Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, 미국, 15224
        • 모병
        • West Penn Hospital
      • York, Pennsylvania, 미국, 17403-5049
        • 모병
        • Cancer Care Associates of York
    • Texas
      • Temple, Texas, 미국, 76508-0001
        • 모병
        • Baylor Scott and White Health Medical Center Temple
      • Tyler, Texas, 미국, 75702-7522
        • 모병
        • Texas Oncology Tyler
      • Belo Horizonte, 브라질, 30110-022
        • 모병
        • CETUS
      • Brasília, 브라질, 70200-730
        • 모병
        • Hospital Sirio Libanes Brasilia
      • Curitiba, 브라질, 81520-060
        • 모병
        • Hospital Erasto Gaertner
      • Florianópolis, 브라질, 88020-210
        • 모병
        • Centro de Ensino E Pesquisa Em Oncologia de Santa Catarina (Cepen)
      • Joinville, 브라질, 89201-260
        • 모병
        • Instituto Joinvilense de Hematologia E Oncologia
      • Niterói, 브라질, 24020-096
        • 모병
        • Complexo Hospitalar de Niteroi
      • Novo Hamburgo, 브라질, 93510-223
        • 모병
        • Vida Hematologia
      • Porto Alegre, 브라질, 90110-270
        • 모병
        • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
      • Rio de Janeiro, 브라질, 22250-040
        • 모병
        • Oncoclinicas Rio de Janeiro Sa
      • Rio de Janeiro, 브라질, 22061-080
        • 모병
        • Hospital Sao Lucas Dasa Oncologia
      • Salvador, 브라질, 41253-190
        • 모병
        • Hospital Sao Rafael (Rede Dor)
      • São Paulo, 브라질, 05652-900
        • 모병
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, 브라질, 04014-002
        • 모병
        • Instituto Brasileiro de Controle Do Cancer
      • São Paulo, 브라질, 01401-004
        • 모병
        • Instituto Dor de Pesquisa E Ensino Sao Paulo
      • Vitória, 브라질, 29043-260
        • 모병
        • Hospital Santa Rita de Cassia Afecc
      • Caba, 아르헨티나, CP1114
        • 모병
        • FUNDALEU
      • Caba, 아르헨티나, C1431
        • 모병
        • CEMIC
      • Caba, 아르헨티나, 1425
        • 모병
        • Hospital Aleman
      • Ciudad Autonoma Buenos Aires, 아르헨티나, 1413
        • 모병
        • Hospital Italiano de Buenos Aires
      • Ciudad Autonoma Buenos Aires, 아르헨티나, 1426
        • 모병
        • Instituto Alexander Fleming (Iaf)
      • San Miguel de Tucumán, 아르헨티나, 4000
        • 모병
        • Cice 9 de Julio Sanatorio 9 de Julio
      • Aberdeen, 영국, AB25 2ZN
        • 모병
        • Aberdeen Royal Infirmary
      • Birmingham, 영국, B9 5SS
        • 모병
        • Birmingham Heartlands Hospital
      • Bournemouth, 영국, BH7 7DW
        • 모병
        • The Royal Bournemouth and Christchurch Hospitals Nhs Foundation
      • London, 영국, SW3 6JJ
        • 모병
        • Royal Marsden Hospital
      • London, 영국, NW1 2PG
        • 모병
        • University College Hospital
      • Southampton, 영국, SO16 6YD
        • 모병
        • Southampton General Hospital
      • Bari, 이탈리아, 70124
        • 모병
        • Irccs Istituto Tumori Giovanni Paolo Ii
      • Florence, 이탈리아, 50134
        • 모병
        • Aou Careggi, Servizio Sanitario Toscana
      • Milan, 이탈리아, 20132
        • 모병
        • Ospedale San Raffaele
      • Milan, 이탈리아, 20122
        • 모병
        • Fondazione Irccs Ca Granda Ospedale Maggiore Policlinico
      • Naples, 이탈리아, 80131
        • 모병
        • Azienda Ospedaliera Universitaria Federico Ii
      • Novara, 이탈리아, 28100
        • 모병
        • Aou Maggiore Della Carita
      • Pavia, 이탈리아, 27100
        • 모병
        • Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi
      • Perugia, 이탈리아, 6129
        • 모병
        • Ospedale Santa Maria Della Misericordia
      • Roma, 이탈리아, 00168
        • 모병
        • Fondazione Policlinico Universitario Agostino Gemelli
      • Kumamoto, 일본, 860-8556
        • 모병
        • Kumamoto University Hospital
      • Okayama, 일본, 701-1192
        • 모병
        • National Hospital Organization Okayama Medical Center
      • Osaka, 일본, 545-8586
        • 모병
        • Osaka Metropolitan University Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, 일본, 464-8681
        • 모병
        • Aichi Cancer Center Hospital Clinical Oncology
    • Chiba
      • Chiba, Chiba, 일본, 260-8717
        • 모병
        • Chiba Cancer Center
    • Ehime
      • Matsuyama, Ehime, 일본, 791-0280
        • 모병
        • Nho Shikoku Cancer Center
    • Hiroshima
      • Hiroshima, Hiroshima, 일본, 730-8619
        • 모병
        • Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
    • Hokkaido
      • Sapporo, Hokkaido, 일본, 064-0804
        • 모병
        • Aiiku Hospital
    • Hyōgo
      • AmagasakiCity, Hyōgo, 일본, 660-8550
        • 모병
        • Hyogo Prefectural Amagasaki General Medical Center
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, 일본, 890-8520
        • 모병
        • Kagoshima University Hospital
    • Kyoto
      • KyotoShi, Kyoto, 일본, 602-8566
        • 모병
        • University Hospital, Kyoto Prefectural Univ of Medicine
    • Miyagi
      • Sendai, Miyagi, 일본, 980-8574
        • 모병
        • Tohoku University Hospital
    • Niigata
      • Niigata, Niigata, 일본, 951-8520
        • 모병
        • Niigata University Medical and Dental Hospital
    • Okayama-ken
      • Kurashikishi, Okayama-ken, 일본, 710-8602
        • 모병
        • Kurashiki Central Hospital
    • Osaka
      • Hirakata, Osaka, 일본, 573-1191
        • 모병
        • Kansai Medical University Hospital
      • Sakai, Osaka, 일본, 590-0197
        • 모병
        • Kindai University Hospital
    • Saitama
      • Kawagoeshi, Saitama, 일본, 350-8550
        • 모병
        • Saitama Medical Center
    • Tokyo
      • Bunkyoku, Tokyo, 일본, 113-8677
        • 모병
        • Tokyo Metropolitan Komagome Hospital
      • Shinagawaku, Tokyo, 일본, 141-0022
        • 모병
        • Ntt Medical Center Tokyo
      • Brno, 체코, 625 00
        • 모병
        • Fakultni Nemocnice Brno
      • Hradec Králové, 체코, 500 03
        • 모병
        • Fakultni Nemocnice Hradec Kralove
      • Ostrava, 체코, 708 00
        • 모병
        • Fakultni Nemocnice Ostrava
      • Prague, 체코, 10000
        • 모병
        • Vseobecna Fakultni Nemocnice V Praze
    • Ontario
      • Hamilton, Ontario, 캐나다, L8V 5C2
        • 모병
        • Juravinski Cancer Centre
      • London, Ontario, 캐나다, N6A 5W9
        • 모병
        • London Health Sciences Centre
      • Ottawa, Ontario, 캐나다, K1H 8L6
        • 모병
        • The Ottawa Hospital Cancer Centre
    • Quebec
      • Greenfield Park, Quebec, 캐나다, J4V 2H1
        • 모병
        • Centre Integre de Sante Et de Services Sociaux de La Monteregie Centre
      • Montreal, Quebec, 캐나다, QC H3t 1E2
        • 모병
        • Jewish General Hospital
      • SaintJerome, Quebec, 캐나다, J7Z 5T3
        • 모병
        • Unite de Recherche Clinique Du Cisss Des Laurentides
      • Ankara, 터키 (Türkiye), 6500
        • 모병
        • Gazi University
      • Ankara, 터키 (Türkiye), 06200
        • 모병
        • Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
      • Balçova, 터키 (Türkiye), 35330
        • 모병
        • Dokuz Eylul University
      • Dokuma, 터키 (Türkiye), 07025
        • 모병
        • Antalya Memorial Hospital
      • Sakarya, 터키 (Türkiye), 54100
        • 모병
        • Sakarya Training and Research Hospital
      • Brzozów, 폴란드, 36-200
        • 모병
        • Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
      • Katowice, 폴란드, 40-519
        • 모병
        • Pratia Onkologia Katowice
      • Krakow, 폴란드, 30-727
        • 모병
        • Pratia McM Krakow
      • Lodz, 폴란드, 93-510
        • 모병
        • Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
      • Lublin, 폴란드, 20-090
        • 모병
        • Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
      • Wroclaw, 폴란드, 50-367
        • 모병
        • Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
    • New South Wales
      • Concord, New South Wales, 호주, NSW 2139
        • 모병
        • Concord Repatriation General Hospital
      • Gosford, New South Wales, 호주, NSW 2250
        • 모병
        • Gosford Hospital
      • Port Macquarie, New South Wales, 호주, NSW 2444
        • 모병
        • Port Macquarie Base Hospital
      • Randwick, New South Wales, 호주, NSW 2031
        • 모병
        • Prince of Wales Hospital
    • Queensland
      • Toowoomba, Queensland, 호주, QLD 4350
        • 모병
        • Toowoomba Hospital
    • South Australia
      • Bedford PK, South Australia, 호주, SA 5042
        • 모병
        • Flinders Medical Centre
    • Victoria
      • Melbourne, Victoria, 호주, VIC 3004
        • 모병
        • The Alfred Hospital
    • Western Australia
      • West Perth, Western Australia, 호주, WA 6005
        • 모병
        • Perth Blood Institute

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria.
  2. Previously received treatment for CLL/SLL with both a BTKi and a BCL2i.
  3. Participants with SLL must have measurable disease by computer tomography (CT)/magnetic resonance imaging (MRI).
  4. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
  5. Adequate liver function.
  6. Adequate blood clotting function.

Exclusion Criteria:

  1. Known prolymphocytic leukemia (defined per iwCLL 2018 as prolymphocytes comprising >55% of peripheral blood lymphocytes), or currently suspected or history of Richter's transformation within the last 5 years.
  2. Prior autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the last 6 months.
  3. Known central nervous system involvement.
  4. Prior exposure to any BTK protein degraders.
  5. Active fungal, bacterial and/or viral infection requiring parenteral systemic therapy.
  6. Clinically significant cardiovascular disease.
  7. Prior invasive fungal infection, except if patient agrees to receive secondary antifungal prophylaxis during the entire treatment period.
  8. Known contraindications to azole antifungal agents, including hypersensitivity reactions.
  9. Receiving systemic immunosuppressive therapy for a nonmalignant condition within 28 days before the first dose of study treatment.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm A: Tacabrutideg monotherapy

Participants will receive tacabrutideg once daily until any of the treatment discontinuation criteria are met

Administered orally

다른 이름들:
  • BGB-16673
활성 비교기: Arm B: Investigator's Choice

Participants will receive investigator's choice of idelalisib plus rituximab for CLL only or bendamustine plus rituximab, or venetoclax plus rituximab retreatment.

Administered orally

Administered intravenously

Administered intravenously

Administered orally

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression-Free Survival (PFS) by Independent Review Committee (IRC)
기간: Approximately 36 Months

PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL).

Approximately 36 Months

2차 결과 측정

결과 측정
측정값 설명
기간
Overall Survival (OS)
기간: Approximately 36 Months

OS is defined as time from the date of randomization to the date of death due to any cause.

Approximately 36 Months
PFS by the Investigator Assessment
기간: Approximately 36 Months

PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by the investigator using modified 2018 iwCLL criteria for participants with CLL and Lugano classification for participants with SLL

Approximately 36 Months
Rate of Partial Response with Lymphocytosis (PR-L) or Higher Determined by IRC and by Investigator Assessment
기간: Approximately 36 Months

Rate of PR-L or higher is defined as the percentage of participants with a best overall response of CR, CRi, nPR, PR, or PR-L as assessed by the IRC or by the Investigator

Approximately 36 Months
Duration of Response (DOR) by IRC and Investigator Assessment
기간: Approximately 36 Months

DOR is defined as the time from initial response to disease progression or death, whichever occurs first, as assessed by the IRC or by the investigator.

Approximately 36 Months
Time to Next Anti-CLL/SLL Treatment (TTNT)
기간: Approximately 36 Months

TTNT is defined as the time from the date of randomization to the date of next anti-CLL/SLL treatment.

Approximately 36 Months
Change from baseline in EORTC Quality of Life Questionnaire - Chronic Lymphocytic Leukemia Module 17 Items (QLQ-CLL17) Symptom Burden and Physical Condition Scales
기간: Approximately 24 Months

The symptom burden and physical condition will be measured by QLQ-CLL17. EORTC QLQ-CLL17 comprises 17 items grouped into 3 multi-item scales: 1) symptom burden, 2) physical condition/fatigue, and 3) worries/fears about health and functioning. Each question is rated using a 4-point response scale ("not at all," "a little," "quite a bit," and "very much") and the recall period for all items is the past 7 days. The scores of each subscale are calculated based on the EORTC's protocol and then transformed to a 0 to 100 scale. Higher scores represent higher levels of symptom burden, physical condition/fatigue, or worries/fears about health and functioning.

Approximately 24 Months
Progression-Free Survival (PFS) in Participants with Prior Exposure to Noncovalent Bruton Tyrosine Kinase Inhibitor(s) (ncBTKi) by IRC
기간: Approximately 36 Months

PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 iwCLL criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL) for participants with prior exposure to ncBTKi.

Approximately 36 Months
Overall Response Rate (ORR) by IRC and Investigator Assessment
기간: Approximately 36 Months

ORR is defined as the percentage of participants with best overall response of complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial remission (nPR), or partial response (PR) as assessed by the IRC or by the investigator.

Approximately 36 Months
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Laboratory Abnormalities
기간: Approximately 36 Months

Safety will be assessed by monitoring and recording of all treatment emergent adverse events (AEs) graded by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.

Approximately 36 Months
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status/QoL (GHS) Physical Functioning and Role Functioning Scales
기간: Approximately 24 Months

The EORTC QLQ-C30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales(fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1=Not at all (best) to 4=Very Much (worst) and 2 questions answered on a 7-point scale where 1=Very poor (worst) to 7=Excellent (best). Higher scores in GHS and functional scales indicate better quality of life.

Approximately 24 Months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Study Director, BeOne Medicines

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 4월 10일

기본 완료 (추정된)

2028년 5월 15일

연구 완료 (추정된)

2030년 2월 14일

연구 등록 날짜

최초 제출

2025년 2월 21일

QC 기준을 충족하는 최초 제출

2025년 2월 21일

처음 게시됨 (실제)

2025년 2월 26일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

IPD 공유 기간

See plan description

IPD 공유 액세스 기준

See plan description

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다